Financial Performance - Abbott's worldwide sales reached $11.1 billion, reflecting a 7.5% increase[3] - Organic sales growth, excluding foreign exchange and the discontinued ZonePerfect product line, showed a growth between 7.5% to 8.0%[3, 6] - Adjusted diluted EPS was $1.26 for the quarter[4] - Full-year 2025 guidance for adjusted diluted EPS is projected to be between $5.10 and $5.20[5] Business Unit Performance - Medical Devices sales amounted to $5.4 billion[4] - Diagnostics sales reached $2.2 billion[4] - Established Pharmaceuticals sales were $1.4 billion[4] Strategic Highlights - The company is expanding its structural heart portfolio[4] - The company is pioneering leadless cardiac pacing[5] - The company is advancing heart rhythm management[7] - FDA approved Abbott's Tendyne™ transcatheter mitral valve replacement (TMVR) system[11] - The AVEIR™ Conduction System Pacing clinical feasibility study is evaluating a leadless pacemaker delivering conduction pacing[12]